Translational Capabilities: Seamless phase I to phase II transition (Milestone 4.Y)
In Progress
Timeline Start - End
2024 - 2025Research Implementation Area
Translational Tools, Infrastructure, and CapabilitiesEvaluate and update current trial funding models to ensure the ability to test novel first-in-class therapeutics in the context of the full range of expenses and time frames required for robust evaluation and sharing.
Success Criteria
- Create a research program that enables academic institutions and small biopharma companies developing first-in-class AD/ADRD therapeutics to conduct first in human trials and seamlessly transition to early-stage clinical trials in the intended patient population.
Summary of Key Accomplishments
This milestone has yet to be initiated. Accomplishments are forthcoming.
The key accomplishments summary is current as of July 2022.